local_hospital

ASST Grande Ospedale Metropolitano Niguarda

Address
lock Available on a paid plan

Hematology and Lymphoma Research

At ASST Grande Ospedale Metropolitano Niguarda, a major focus is hematologic malignancies, with studies in classical Hodgkin lymphoma, non-Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, and other rare B-cell cancers. These trials are designed to test new treatment combinations, improve disease control, and evaluate better options for patients whose disease has returned or is difficult to treat.

  • Classical Hodgkin lymphoma and pediatric/young adult lymphomas are being studied to assess treatment response and safety of newer immunotherapy approaches.
  • Follicular lymphoma, marginal zone lymphoma, and related indolent lymphomas are included in studies comparing targeted therapies and combination regimens.
  • Chronic lymphocytic leukemia, Waldenström macroglobulinemia, hairy cell leukemia, and other rare B-cell disorders are being investigated to improve outcomes in relapsed or previously untreated disease.

This work reflects a strong Clinical Trial Unit expertise in blood cancers, with attention to both standard and innovative treatment strategies.

Cardiovascular Disease Prevention and Treatment

The site is active in cardiovascular diseases, including atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, and stroke prevention. Research here often focuses on whether new medicines can lower the risk of major cardiac and vascular events, improve long-term protection, and offer alternatives for patients who cannot use standard therapies.

  • Atherosclerotic cardiovascular disease and high-risk prevention are being studied to reduce heart attack and stroke risk.
  • Atrial fibrillation trials are evaluating safer ways to prevent embolic events.
  • Chronic heart failure and broader cardiovascular outcomes research aim to improve survival and reduce hospitalizations.

Several studies at ASST Grande Ospedale Metropolitano Niguarda also examine cholesterol and triglyceride disorders, linking prevention with everyday cardiovascular care.

Oncology Across Solid Tumors

A broad neoplasms portfolio covers colorectal cancer, lung cancer, ovarian cancer, endometrial cancer, pancreatic cancer, biliary tract cancer, and head and neck cancer. The main goal is to evaluate new immunotherapy, targeted therapy, and peri-operative treatment approaches that may improve response rates, delay progression, or make surgery more effective.

  • Colorectal cancer studies include both resectable and metastatic disease, with interest in pre-operative and post-treatment strategies.
  • Non-small cell lung cancer, ovarian cancer, and head and neck squamous cell carcinoma are being explored with immunotherapy-based combinations.
  • Biliary tract, pancreatic, and endometrial cancers are included in trials seeking better control of advanced or recurrent disease.

This oncology research supports personalized treatment selection and more effective care for patients with difficult-to-treat solid tumors.

Liver, Digestive, and Metabolic Disorders

The research program also includes digestive system diseases and nutritional and metabolic diseases, such as Crohn's disease, primary biliary cholangitis, portal hypertension, cirrhosis, type 2 diabetes, and lipid disorders. These trials are aimed at improving symptom control, slowing disease complications, and testing therapies that may better manage long-term metabolic and liver-related conditions.

  • Crohn's disease research focuses on maintaining disease control in patients who respond to treatment.
  • Primary biliary cholangitis and cirrhosis with portal hypertension studies are evaluating options for itching and liver pressure-related complications.
  • Type 2 diabetes, hypercholesterolemia, and hypertriglyceridemia trials are looking at better metabolic management and cardiovascular risk reduction.

The clinical work at ASST Grande Ospedale Metropolitano Niguarda connects liver care, gastroenterology, and metabolic medicine in a practical hospital setting.

Neurology, Eye Care, and Public Health Studies

Additional research spans nervous system diseases, eye diseases, and environment and public health. This includes trials in stroke, intracerebral hemorrhage, dyskinesia due to cerebral palsy, and pediatric eye anesthesia, along with studies on infectious disease and critically ill patients. The purpose is to improve everyday clinical care, support recovery, and assess practical treatment approaches in both adults and children.

  • Stroke and intracerebral hemorrhage research is examining ways to improve urgent care and early outcomes.
  • Dyskinesia due to cerebral palsy studies are focused on symptom relief and better movement control.
  • Eye disease research includes pediatric procedures designed to make clinical exams more comfortable and effective.

The site also contributes to infectious disease and critical care research, including studies related to mpox and emergency airway management.

Site Overview

assignment
413
connected trials
corporate_fare
162
sponsors
science
500
IMPs

Activity Indicator

Last 6 months

30
Trials started
-48% vs previous period.
58
Trials started 6–12 months ago
413
Total trials linked
Highly Active
trending_downDeclining-48%
7
8
5
5
4
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 22 therapeutic areas and 15 of 500 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 483 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
218
Sponsors (total)
162
Active sponsors
115

Sponsor Network

Top 115 by active trials.

lock +114 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +62 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
413
Outperforms 97% of sites
public
Therapeutic diversity
22areas
Outperforms 93% of sites
groups
Sponsor diversity
162sponsors
Outperforms 97% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in ASST Grande Ospedale Metropolitano Niguarda

lock Showing 1 of 413 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 500 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Fluorouracil31Unknown2018-03-282026-07-20

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.